The clock is ticking for Gerresheimer. The German packaging specialist is navigating a perfect storm of regulatory scrutiny, delayed financial reporting, and operational headwinds — all while trying to sell a key subsidiary to shore up its balance sheet. The next few months will determine whether the company can restore market confidence or sink deeper into crisis.
A Leasing Error at the Heart of the Crisis
The root cause of Gerresheimer’s troubles is a leasing accounting error worth €65.5 million. Employees are suspected of violating IFRS standards, triggering an investigation by Germany’s financial regulator, BaFin. The probe, launched in September 2025, has since expanded to include two additional issues: the misstatement of useful lives for capitalized development costs (book value: €29.4 million) and the failure to properly record impairment charges on assets in the Advanced Technologies segment (book value: €196.5 million).
The fallout has been severe. The audited financial statements for 2025 — originally due months ago — are now not expected until June 2026, according to the company. One source puts the timeline even later, pointing to end-September 2026. Either way, the delay has paralyzed Gerresheimer’s financial calendar. The half-year report, scheduled for July 14, cannot be published until the annual accounts are signed off.
Creditors Step In, But Doubts Linger
In a rare show of support, 96% of Gerresheimer’s lenders have agreed to waive key debt covenants tied to leverage ratios through the third quarter. The reprieve buys the company time but does not resolve the underlying problem. Without audited accounts, institutional investors lack the clarity needed to take a position on the stock.
The market has already delivered its verdict. The shares trade at around €22.76, roughly 65% below their 52-week high of €64.40. On an annual basis, the stock has shed nearly 58% of its value. Although it has recovered somewhat from its February trough, year-to-date losses still stand at about 18%.
BaFin’s Findings Could Shift the Ground
The regulator has not set a timeline for publishing its conclusions. But when they come, they could force Gerresheimer to restate prior-year figures. The company’s 2026 guidance — revenue between €2.3 billion and €2.4 billion, adjusted EBITDA margin of 18% to 19%, and moderately positive free cash flow — is explicitly conditional on a favorable outcome from BaFin.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Market observers question whether those targets are achievable, especially as operational pressures mount. Gerresheimer, a major producer of glass packaging, is highly energy-intensive. Rising electricity prices in March have added to margin strain, compounding the damage from the accounting scandal.
Centor Sale as a Lifeline
To strengthen its financial position, Gerresheimer is pushing ahead with the sale of its US subsidiary Centor, which makes packaging systems for prescription drugs. Morgan Stanley is advising on the transaction, and the company reports a “double-digit number” of interested parties. A deal is expected to close in 2026, with proceeds earmarked for debt reduction.
The sale is part of a broader strategy to stabilize the financing structure. But it is not a silver bullet. The true extent of Gerresheimer’s balance-sheet problems will only become clear once the audited accounts are published.
A Pivotal Juncture
All eyes are now on June. The annual general meeting is set for June 3, where management must present a credible recovery plan to shareholders. Later that month, the revised 2025 figures are expected to land. Only then will investors get a full picture of the damage — and a basis for revaluing the stock.
For now, Gerresheimer is living on borrowed time — both literally and figuratively. The creditor waiver provides a cushion, but the underlying issues remain unresolved. The next few weeks will show whether the company can turn the corner or whether the crisis deepens further.
Ad
Gerresheimer Stock: Buy or Sell?! New Gerresheimer Analysis from April 25 delivers the answer:
The latest Gerresheimer figures speak for themselves: Urgent action needed for Gerresheimer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 25.
Gerresheimer: Buy or sell? Read more here...
